Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 38 | 2025 | 518 | 7.900 |
Why?
|
| Neoplasms | 18 | 2025 | 1377 | 3.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 24 | 2021 | 968 | 2.200 |
Why?
|
| Killer Cells, Natural | 4 | 2025 | 104 | 2.150 |
Why?
|
| Exosomes | 9 | 2020 | 126 | 1.910 |
Why?
|
| Cell Communication | 6 | 2025 | 114 | 1.850 |
Why?
|
| RNA, Neoplasm | 4 | 2021 | 25 | 1.660 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 495 | 1.250 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 307 | 1.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 133 | 1.150 |
Why?
|
| Neuroblastoma | 3 | 2021 | 136 | 1.120 |
Why?
|
| Immunotherapy | 4 | 2021 | 144 | 1.110 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2018 | 61 | 0.770 |
Why?
|
| Toll-Like Receptors | 2 | 2013 | 51 | 0.760 |
Why?
|
| RNA | 2 | 2023 | 266 | 0.750 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2021 | 21 | 0.720 |
Why?
|
| RNA, Untranslated | 2 | 2019 | 50 | 0.720 |
Why?
|
| Humans | 53 | 2025 | 43102 | 0.710 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 56 | 0.700 |
Why?
|
| Animals | 29 | 2025 | 16992 | 0.670 |
Why?
|
| Conserved Sequence | 2 | 2017 | 122 | 0.650 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 159 | 0.650 |
Why?
|
| Oncogenes | 2 | 2018 | 44 | 0.640 |
Why?
|
| Dendritic Cells | 3 | 2017 | 132 | 0.640 |
Why?
|
| Mutation | 2 | 2021 | 1177 | 0.510 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2021 | 347 | 0.490 |
Why?
|
| Cell Proliferation | 9 | 2018 | 1455 | 0.440 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 228 | 0.440 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 30 | 0.420 |
Why?
|
| Signal Transduction | 5 | 2017 | 2157 | 0.390 |
Why?
|
| Mice | 16 | 2021 | 6644 | 0.390 |
Why?
|
| Melanoma | 1 | 2014 | 110 | 0.390 |
Why?
|
| Monocytes | 1 | 2015 | 277 | 0.390 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 2676 | 0.380 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 178 | 0.370 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 291 | 0.360 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 51 | 0.350 |
Why?
|
| Mice, SCID | 3 | 2021 | 158 | 0.340 |
Why?
|
| Tumor Escape | 2 | 2019 | 17 | 0.280 |
Why?
|
| Inflammation | 2 | 2017 | 758 | 0.280 |
Why?
|
| Cisplatin | 3 | 2018 | 98 | 0.270 |
Why?
|
| Stromal Cells | 2 | 2016 | 55 | 0.230 |
Why?
|
| Female | 17 | 2023 | 24698 | 0.220 |
Why?
|
| Mice, Nude | 6 | 2017 | 408 | 0.220 |
Why?
|
| Immunity, Innate | 2 | 2016 | 171 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 41 | 0.200 |
Why?
|
| Apoptosis | 6 | 2018 | 1568 | 0.200 |
Why?
|
| Toll-Like Receptor 8 | 3 | 2022 | 5 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 184 | 0.190 |
Why?
|
| Transplantation, Homologous | 2 | 2019 | 38 | 0.190 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 291 | 0.180 |
Why?
|
| Ligands | 2 | 2013 | 388 | 0.170 |
Why?
|
| RNA, Messenger | 4 | 2020 | 1271 | 0.170 |
Why?
|
| Disease Progression | 3 | 2021 | 667 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 32 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2021 | 51 | 0.170 |
Why?
|
| Down-Regulation | 4 | 2017 | 456 | 0.170 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 37 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 290 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 508 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 259 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2014 | 638 | 0.160 |
Why?
|
| Male | 11 | 2021 | 23409 | 0.160 |
Why?
|
| Base Sequence | 3 | 2017 | 983 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 81 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1019 | 0.150 |
Why?
|
| RNA, Viral | 1 | 2020 | 321 | 0.150 |
Why?
|
| Leukemia | 2 | 2010 | 54 | 0.150 |
Why?
|
| Nucleic Acid Conformation | 1 | 2019 | 154 | 0.140 |
Why?
|
| NF-kappa B | 3 | 2017 | 358 | 0.140 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2018 | 1 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2017 | 536 | 0.140 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2018 | 97 | 0.140 |
Why?
|
| Cyclins | 1 | 2017 | 34 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 51 | 0.140 |
Why?
|
| Prognosis | 5 | 2017 | 861 | 0.140 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2017 | 18 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 512 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2018 | 96 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2010 | 704 | 0.130 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2017 | 1 | 0.130 |
Why?
|
| Keratinocytes | 1 | 2017 | 67 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 15 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 81 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 54 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1604 | 0.120 |
Why?
|
| RNA Transport | 1 | 2016 | 1 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 1723 | 0.120 |
Why?
|
| Proteins | 1 | 2019 | 382 | 0.120 |
Why?
|
| Lung | 2 | 2017 | 492 | 0.120 |
Why?
|
| Viruses | 1 | 2016 | 39 | 0.120 |
Why?
|
| DNA | 1 | 2019 | 592 | 0.120 |
Why?
|
| Oxidoreductases | 2 | 2007 | 79 | 0.120 |
Why?
|
| Biological Transport | 1 | 2016 | 204 | 0.120 |
Why?
|
| Immune System | 1 | 2016 | 41 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2023 | 652 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2016 | 124 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 376 | 0.120 |
Why?
|
| Cell Lineage | 2 | 2014 | 104 | 0.120 |
Why?
|
| Models, Molecular | 1 | 2019 | 876 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 213 | 0.120 |
Why?
|
| Sepsis | 1 | 2016 | 90 | 0.120 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 3 | 0.120 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 18 | 0.120 |
Why?
|
| Transcription, Genetic | 3 | 2015 | 592 | 0.120 |
Why?
|
| Paracrine Communication | 1 | 2015 | 18 | 0.110 |
Why?
|
| Telomere-Binding Proteins | 1 | 2015 | 11 | 0.110 |
Why?
|
| Galectin 3 | 1 | 2015 | 30 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 139 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 89 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 165 | 0.110 |
Why?
|
| Coculture Techniques | 1 | 2015 | 109 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 8 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 34 | 0.110 |
Why?
|
| Transfection | 5 | 2015 | 532 | 0.100 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2013 | 27 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 415 | 0.100 |
Why?
|
| Macrophages | 1 | 2016 | 529 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 223 | 0.090 |
Why?
|
| Carcinoma | 1 | 2011 | 108 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 38 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 712 | 0.070 |
Why?
|
| Protein Binding | 1 | 2012 | 1082 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 306 | 0.070 |
Why?
|
| Endometrial Neoplasms | 1 | 2010 | 79 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 678 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 241 | 0.070 |
Why?
|
| Cytogenetics | 1 | 2008 | 3 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2008 | 8 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2007 | 223 | 0.070 |
Why?
|
| Multigene Family | 1 | 2008 | 105 | 0.070 |
Why?
|
| Middle Aged | 7 | 2018 | 12222 | 0.060 |
Why?
|
| Aged | 6 | 2018 | 8214 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 2853 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 1857 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 35 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2023 | 121 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2018 | 403 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 374 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 203 | 0.040 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 1092 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 268 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2014 | 43 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2015 | 1035 | 0.040 |
Why?
|
| Cell Movement | 2 | 2016 | 655 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 1081 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 1869 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 310 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 11 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 934 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 386 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 150 | 0.030 |
Why?
|
| RNA Editing | 1 | 2018 | 37 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2009 | 150 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 883 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 70 | 0.030 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2017 | 12 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 108 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 2016 | 16 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 155 | 0.030 |
Why?
|
| Adult | 4 | 2018 | 13872 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 165 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2017 | 172 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 665 | 0.030 |
Why?
|
| Austria | 1 | 2015 | 5 | 0.030 |
Why?
|
| Romania | 1 | 2015 | 7 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 27 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 60 | 0.030 |
Why?
|
| Galectins | 1 | 2015 | 30 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2015 | 77 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 384 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 436 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 173 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 220 | 0.030 |
Why?
|
| Endocytosis | 1 | 2015 | 118 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 440 | 0.030 |
Why?
|
| Poly I-C | 1 | 2013 | 7 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 863 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 611 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2013 | 181 | 0.020 |
Why?
|
| Tretinoin | 1 | 2013 | 50 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 1759 | 0.020 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 2012 | 2 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2012 | 40 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2012 | 32 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 44 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 84 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 247 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 150 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 173 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 75 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 368 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1285 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1596 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 12 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Trisomy | 1 | 2008 | 11 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 45 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 31 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1067 | 0.020 |
Why?
|
| Proteome | 1 | 2008 | 152 | 0.020 |
Why?
|
| Stem Cells | 1 | 2008 | 152 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2006 | 21 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2006 | 62 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 701 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 98 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 129 | 0.020 |
Why?
|
| Cell Line | 1 | 2010 | 1410 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 1621 | 0.010 |
Why?
|
| Proteomics | 1 | 2008 | 378 | 0.010 |
Why?
|
| Adolescent | 1 | 2008 | 6081 | 0.010 |
Why?
|